drugset / Trial / NCT05642910
The Efficacy of Azvudine and Paxlovid in High-risk Patients With COVID-19: A Prospective Randomized Controlled Trial
Unknown
540 enrolled
Southeast University, China
Hohhot First Hospital, Hohhot, Inner Mongolia, China · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized controlled clinical study on the clinical efficacy of Azvudine and Paxlovid antivirus therapy in COVID-19 patients with high-risk. The objective is to examine the effect of high-risk on the time for COVID-19 patients to achieve 2 continuously negative SARS-CoV-2 nucleic acid test result, and the RT-PCR negative conversion rates in day 7. Patients who meet inclusion criteria will be randomized into the Azvudine group (treatment group) and Paxlovid group (control group).
Timeline
- Start
- 2022-10-18
- Primary completion
- 2023-01-31
- Completion
- 2023-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azvudine | Small molecule | — | Oral |
| Comparator | Nirmatrelvir | Small molecule | — | Oral |